MedTrace Logo

Platelet Rich Plasma Eye Drops for Treatment of Ocular Surface Disease

NCT04608084 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2020-10-29

No results posted yet for this study

Summary

The purpose of this study is to evaluate prospectively the efficacy of topical administration of autologous platelet rich plasma as monotherapy for the treatment of symptoms and clinical signs in cases affected by moderate to severe forms of ocular surface disease

Conditions

  • Ocular Surface Disease
  • Dry Eye Syndromes

Interventions

BIOLOGICAL

Autologous platelet rich plasma eye drops

Participant own blood is used for the preparation of Autologous platelet rich plasma eye drops

Sponsors & Collaborators

  • University Health Network, Toronto

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-31
Primary Completion
2022-01-31
Completion
2023-01-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04608084 on ClinicalTrials.gov